Issuance of Patent #7,338,961

Apogee is pleased to announce the issuance of U.S. patent #7,338,961, entitled “Sphingosine kinase inhibitors.”

This patent is the first issue in a series of domestic and international filings protecting Apogee’s sphingosine kinase inhibitor program.  Importantly, this patent specifically protects the lead compound of development, ABC294640, and related chemotypes.

Powered by THE BRAVO GROUP & ARCHODA: CREATE SOMETHING UNIQUE